Cookie Policy

A full description of our cookie policy can be found here.

Essential (Required)

Cookies that the site cannot function without. This includes cookies for access to secure areas and CSRF protection. Please note that Craft's default cookies do not collect any personal or sensitive information. Craft's default cookies do not collect IP addresses. The information they store is not sent to Pixel & Tonic or any 3rd parties.

Name: CraftSessionId
Description: Craft relies on PHP sessions to maintain sessions across web requests. That is done via the PHP session cookie. Craft names that cookie “CraftSessionId” by default, but it can be renamed via the phpSessionName config setting. This cookie will expire as soon as the session expires.
Provider: biocatalysts.com
Expiry: Session

Name: *_identity
Description: When you log into the control panel, you’ll get an authentication cookie used to maintain your authenticated state. The cookie name is prefixed with a long, randomly generated string, followed by _identity. The cookie only stores information necessary to maintain a secure, authenticated session and will only exist for as long as the user is authenticated in Craft.
Provider: biocatalysts.com
Expiry: Persistent

Name: *_username
Description: If you check the "Keep me logged in" option during login, this cookie is used to remember the username for your next authentication.
Provider: biocatalysts.com
Expiry: Persistent

Name: CRAFT_CSRF_TOKEN
Description: Protects us and you as a user against Cross-Site Request Forgery attacks.
Provider: biocatalysts.com
Expiry: Session

Media and Resources

Application Solutions, Case Studies, News, Events: here you find resources related to your industry sector, and where to meet us at events coming soon.

Home/ Media & Resources

Search & filter articles

117 Articles

3 Sept 2025

BRAIN Biotech AG appoints Johan Jansén-Storbacka as Executive Vice President of the BRAINBiocatalysts´ enzyme products business

Jansén-Storbacka succeeds Rod Sears-Black, who retired on January 1, 2025.

28 Aug 2025

BRAIN Biotech reports dynamic Q3 revenue growth in core segment BRAINBiocatalysts

BRAIN Biotech AG, a leading provider of specialised enzymes and innovative biological solutions for industry, has published its financial results for the first nine months of the 2024/25 fiscal year.

21 Aug 2025

Unlocking the Power of Biocatalysis for Complex Molecules and Novel Modalities

From chiral amines and nucleoside analogues to non-canonical amino acids and oligonucleotides, pharmaceutical pipelines are evolving - and so must the tools that support them.

31 Jul 2025

How Enzymes Enhance Collagen: A Closer Look at Functionality and Processing

Discover how enzymes unlock collagen’s true potential in food and beverage innovation. This blog reveals how enzymatic hydrolysis turns tough, insoluble collagen into smooth, bioavailable peptides perfect for functional nutrition.

23 Jul 2025

What We Thought vs. What’s Really Cooking: How are Enzymes Powering 2025’s Food Trends

At the start of 2025, industry experts painted a bold, exciting picture of where food was heading

21 Jul 2025

Collagen: The Secret Support System in Your Body

You’ve seen it in beauty serums, smoothie powders, even joint supplements. But what is collagen, why does your body need it, and how does it actually work? it’s not just the collagen that matters, it’s what enzymes do to it.

9 Jul 2025

Reflections from Biotrans 2025: Charting the Future of Biocatalysis in Pharmaceuticals

More than 650 industry leaders, academic pioneers, and technology disruptors travelled to Basel to the most impactful biocatalysis conference of the year. Read our take on the key discussions, trends and industry challenges from Biotrans 2025.

20 Jun 2025

Strain Engineering & Optimisation Driving Pharmaceutical and Life Science Innovation

In pharmaceutical and life science applications, enzymes aren’t just molecules they’re critical tools driving innovation in therapeutics, diagnostics, and bioprocessing. But without the right production strain, even the most promising enzyme can fail to scale.